A 200 mg/mL calcium disodium edetate solution intended for slow intravenous infusion in cattle is prepared in a closed 316L stainless steel jacketed vessel fitted with a bottom magnetic stirrer and nitrogen overlay. The compounding process begins with the addition of 800 g calcium disodium edetate to 4.0 L of water for injection at 25±5°C, with mixing at 350 rpm until complete dissolution. The pH is adjusted to 7.0–7.5 using 1 N sodium hydroxide or 1 N hydrochloric acid; pH adjustment is performed slowly to avoid localized pH excursions that could promote calcium displacement from the chelate. The solution is brought to final volume with water for injection and then passed through a 0.22 μm polyethersulfone filter at 2.0–3.0 bar into a sterilized filling manifold. The filtered bulk is filled into 100 mL Type I borosilicate glass vials under ISO Class 5 laminar airflow, stoppered with bromobutyl rubber closures, and sealed with aluminum flip-off caps. Terminal sterilization is by steam autoclaving at 121°C for 15 minutes, yielding a sterility assurance level of 10⁻⁶ and a cumulative lethality of F₀ ≥ 8. Compendial compliance for this dosage form includes the current USP monograph for Calcium Disodium Edetate, which specifies an assay of 97.0–102.0% on the dried basis, and USP <1> Injections, USP <85> Bacterial Endotoxins, USP <788> Particulate Matter in Injections, and USP <791> pH. Endotoxin limits are established based on the intended maximum bolus dose per kilogram body weight; typical veterinary infusion protocols dilute the 200 mg/mL solution to 1–2% (i.e., 10–20 mg/mL) in 0.9% sodium chloride or 5% dextrose before slow intravenous administration. The terminal product is a 100 mL amber glass vial containing a sterile, clear, colorless to pale yellow solution, labelled for single-use intravenous infusion in cattle with a beyond-use date assigned according to VICH GL3 stability data. Because calcium disodium edetate chelates endogenous zinc, copper, and manganese, post-infusion monitoring of serum trace elements is a documented operational boundary; supplemental trace mineral therapy is commonly required after chelation cycles.

Lyophilization Cycle Boundaries for Equine Calcium Disodium Edetate Injection Powders

Lyophilized calcium disodium edetate for equine practice is formulated at 200 mg active per 20 mL Type I borosilicate glass vial, with 40 mg mannitol as a crystalline bulking agent to prevent cake collapse. The solution is filtered through a 0.22 μm PVDF filter and filled to 10 mL per vial before loading into a lyophilizer with a condenser temperature of -65°C. The freeze-drying cycle uses a shelf ramp of 1.0°C/min to -40°C, holding for 4 hours; primary drying is conducted at a shelf temperature of -20°C and chamber pressure of 100 mTorr, with the endpoint determined by comparative pressure measurement (Pirani vs. capacitance manometer). Secondary drying increases the shelf temperature to 25°C and holds for 6 hours under vacuum. Residual moisture is measured by USP <921> Method Ia Karl Fischer titration and must remain ≤1.0% w/w to ensure a non-collapsed, pharmaceutically acceptable cake. The vials are stoppered under vacuum and sealed with aluminum tear-off caps. Relevant compendial methods include USP <1> Injections, USP <85> Bacterial Endotoxins, USP <788> Particulate Matter in Injections, and USP <791> pH; container closure integrity is evaluated according to USP <1207>. Residual solvent limits follow VICH GL18(R2) and are derived from ICH Q3C; ethanol, if used in any upstream crystallization, is controlled at ≤5,000 ppm. The terminal product is a sterile lyophilized powder in a 20 mL amber vial, reconstituted with 10 mL water for injection to give a 20 mg/mL solution, which is further diluted with 0.9% sodium chloride to 1–2% for slow intravenous infusion. The lyophilized presentation addresses long-term storage stability requirements in mixed equine practice settings where liquid formulations may be exposed to temperature excursions during transport. Published stability data for this specific vial configuration is limited; assignment of beyond-use dating should be based on site-specific VICH GL3 protocols rather than extrapolation from aqueous solution kinetics.

For avian and exotic animal compounding, oral granules containing 5.0% w/w calcium disodium edetate are manufactured by high-shear wet granulation to improve content uniformity in small divided doses. The formulation consists of 5.0 g calcium disodium edetate, 80.0 g lactose monohydrate, 10.0 g microcrystalline cellulose, and 5.0 g povidone K-30 per 100 g batch. The dry powders are mixed in a high-shear granulator at 200 rpm impeller speed and 1,500 rpm chopper speed for 5 minutes. A 10% w/w ethanolic povidone solution is added at 8 g/min to the moving powder bed until a moisture content of 12% w/w is achieved; wet massing continues for 3 minutes. The wet granules are discharged through a 2.0 mm screen, dried in a fluid bed dryer at 50°C inlet air temperature until loss on drying is ≤2.0% w/w, and then milled through a 1.0 mm screen. The final granules are filled into 3 g foil sachets, each delivering 150 mg calcium disodium edetate. Compendial testing includes USP <905> Uniformity of Dosage Units, USP <711> Dissolution, and USP <795> for nonsterile preparations when applicable; content uniformity across 10 sachets must exhibit an acceptance value ≤15. The terminal product is intended for in-food administration to psittacine birds with confirmed heavy metal exposure. Published efficacy data for this specific avian oral configuration is limited; veterinarians typically rely on parenteral protocols first and reserve oral granules for follow-up gastrointestinal decontamination where the chelator is not expected to achieve high systemic bioavailability because intestinal absorption of the calcium disodium edetate complex is <5%. The operational boundary is therefore limited to binding unabsorbed lead in the gastrointestinal tract, not to systemic mobilization of lead from bone or soft tissue depots.

What Happens to Tablet Hardness When Polyvalent Metal Stearates Are Omitted from a Direct-Compression Chelator Blend?

Direct compression of calcium disodium edetate into 200 mg tablets requires exclusion of magnesium stearate and other polyvalent metal stearates because the chelator binds the magnesium ion, reducing lubricant efficacy and causing tool binding at higher compression forces. A formulation per tablet is composed of 200 mg calcium disodium edetate, 150 mg microcrystalline cellulose, 12 mg crospovidone, 4 mg colloidal silicon dioxide, and 4 mg sodium stearyl fumarate. The blend is deagglomerated through a 850 μm screen and mixed in a bin blender at 25 rpm for 15 minutes. Compression is performed on a rotary tablet press at 10–20 kN main compression force, with a pre-compression force of 2–4 kN and a turret speed of 30–50 rpm. Target tablet hardness is 60–80 N, measured by USP <1217> Tablet Breaking Force, and disintegration time must meet USP <701> with a limit of ≤15 minutes in 0.1 N hydrochloric acid at 37°C. Dissolution is evaluated according to USP <711> with Apparatus 2 (paddle) at 50 rpm in 900 mL of 0.1 N hydrochloric acid; release of ≥80% within 30 minutes is typically specified for immediate-release chelator tablets. The terminal product is a 200 mg round, flat-faced bevel-edged tablet packaged in PVC/PVDC blisters, intended for off-label oral chelation in dogs under veterinary supervision. Because oral absorption of calcium disodium edetate is <5%, systemic chelation from this dosage form is limited; the tablet functions primarily as a gastrointestinal lead-binding agent. Published data on the systemic efficacy of oral calcium disodium edetate tablets in dogs is limited and does not support substitution for parenteral chelation in acute plumbism. The formulation should not be combined with mineral supplements containing calcium, zinc, iron, or magnesium within 2 hours of administration because these ions compete for chelation and reduce the available binding capacity for lead.

Because hard gelatin capsule filling demands lower water activity than tableting, a dry granulated calcium disodium edetate blend is compacted into slugs before encapsulation to avoid wet granulation and the associated residual moisture risk. Each capsule contains 150 mg calcium disodium edetate, 120 mg anhydrous lactose, 8 mg croscarmellose sodium, and 5 mg sodium stearyl fumarate. The blend is passed through a roller compactor with a roll force of 8 kN/cm and roll speed of 5 rpm, then milled through a 1.0 mm screen to produce granules with a fines fraction ≤25%. The granules are filled into size 2 hard gelatin capsules on an automatic capsule filling machine at 12,000 capsules/hour. In-process checks include capsule weight variation ±5%, disintegration time per USP <701> ≤15 minutes, and moisture content by USP <731> Loss on Drying ≤5.0% w/w. Compendial release testing for the capsule dosage form includes USP <905> Uniformity of Dosage Units and USP <711> Dissolution using Apparatus 2 at 50 rpm in 0.1 N hydrochloric acid. The terminal product is a 150 mg hard gelatin capsule packaged in 60-count HDPE bottles with desiccant and child-resistant closures, intended for feline oral administration under veterinary compounding practice. The moisture limit is critical because higher water activity can plasticize the gelatin shell and accelerate cross-linking; storage conditions are maintained at 25°C/60% RH or lower. As with the tablet form, systemic absorption is minimal, and the capsule is an adjunct to primary parenteral therapy rather than a standalone chelation treatment.

Medicated Feed Premix Homogeneity and Heavy Metal Sequestration in Swine

A 5.0% w/w calcium disodium edetate medicated premix for in-feed administration to swine is prepared by stepwise geometric dilution in a horizontal ribbon blender to achieve uniformity before dilution into complete feed. The formula per 1,000 kg batch includes 50 kg calcium disodium edetate, 400 kg limestone carrier, and rice hulls to 1,000 kg. Blending is performed at 20 rpm for 20 minutes after a 5-minute pre-blend of the active with an equal portion of carrier. Homogeneity is confirmed by taking 10 samples across the blender and analyzing for EDTA content via liquid chromatography, with acceptance limits of 90–110% of label claim and relative standard deviation ≤5%. Regulatory compliance for medicated feed premixes in the United States falls under 21 CFR Part 225 Current Good Manufacturing Practice for Medicated Feeds; equipment and work area standards are specified in 21 CFR 225.58, and component controls in 21 CFR 225.42. The terminal product is a 25 kg multiwall paper bag with an inner polyethylene liner, labelled for in-feed use only. Published data on the systemic efficacy of oral calcium disodium edetate in production swine is limited; the premix is positioned for gastrointestinal heavy metal binding, not for systemic chelation. The operational boundary is that dietary calcium, zinc, copper, and iron compete with lead for the chelator, so feed mineral concentrations must be considered when calculating the effective binding capacity. This application does not replace approved parenteral therapies and may be subject to regional registration under EU Regulation 2019/6 or national veterinary medicinal product frameworks.

When Trace-Metal Scavenging in Multivitamin Infusion Solutions Requires a Calcium-Substituted Chelator

In multivitamin infusion solutions, calcium disodium edetate functions as a trace-metal scavenger at 0.05% w/v to sequester catalytic metal ions that accelerate oxidative degradation of thiamine, riboflavin, and ascorbic acid. The use of the calcium-substituted form instead of disodium edetate minimizes the risk of ionized calcium depletion in the infusion. The formulation is prepared by dissolving the vitamins and 0.5 g calcium disodium edetate per 1.0 L in nitrogen-purged water for injection, adjusting the pH to 5.0–6.0, and filtering through a 0.22 μm PES membrane before filling into 100 mL Type I amber glass vials. Terminal sterilization is by autoclaving at 121°C for 15 minutes. The solution is tested according to USP <1> Injections, USP <85> Bacterial Endotoxins, USP <788> Particulate Matter in Injections, USP <791> pH, and VICH GL18(R2) for residual solvents. The terminal product is a sterile multivitamin infusion solution in a 100 mL vial, intended for dilution into 0.9% sodium chloride or 5% dextrose before intravenous infusion in cattle, horses, or companion animals. The calcium disodium edetate content is below therapeutic chelation levels; its role is stabilizer, not active. Incompatibility is observed with phosphate-containing solutions because calcium edetate can precipitate as calcium phosphate under certain pH and concentration conditions; admixture compatibility should be tested according to USP <788> Particulate Matter in Injections and visual inspection protocols before compounding.